Liproxstatin-1 is able to inhibit ferroptosis in the low nanomolar range and inhibit the growth of Gpx4cells with IC50 of 22 nM. Liproxstatin-1 (50 nM) completely prevents lipid peroxidation in Gpx4cells. Liproxstatin-1 (200 nM) protects against FINs, such as BSO (10 µM), erastin (1 µM) and RSL3 (0.5 µM), in a dose dependent manner, whereas it fails to rescue cell death induced by staurosporine (0.2 µM) and HO (200 µM).
In vivo
Liproxstatin-1 remarkably extends survival compared with the vehicle-treated group, delays ferroptosis in tubular cells, and mitigates tissue injury in ischaemia/reperfusion-induced liver injury.